Cellectar Biosciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 37.98 million compared to USD 28.6 million a year ago. Basic loss per share from continuing operations was USD 3.11 compared to USD 4.05 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.525 USD | -12.63% | -8.57% | -7.58% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.58% | 10Cr | |
+54.66% | 81TCr | |
+43.62% | 64TCr | |
-6.72% | 35TCr | |
+18.13% | 33TCr | |
+8.87% | 30TCr | |
+16.30% | 25TCr | |
+2.41% | 22TCr | |
+12.47% | 22TCr | |
+9.24% | 17TCr |
- Stock Market
- Equities
- CLRB Stock
- News Cellectar Biosciences, Inc.
- Cellectar Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023